biologics
‘The confidence is not there.’
Biosimilar switching and even administration will be significant parts of full scope of practice – but pharmacists need confidence, says a sector leader Pharmacy stakeholders went to Parliament House, Canberra …
Clinical tips: Biologicals and biosimilars
Biosimilars and the pharmacist’s role in their supply remains controversial, writes Carlene McMaugh Biological pharmaceutical products have been a part of the landscape of therapeutics for a number of years …
Biologics switching is in pharmacists’ scope
Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, says FIP The International Pharmaceutical Federation has published a revised Statement of …
The inevitable rise of biosimilars
In the latest in our series based on 2017 UTS Pharmacy Barometer results, John Montgomery looks at how pharmacists view the riding tide of biosimilar medicines There’s little doubt biosimilar …
Patents extended under revived TPP?
The ACTU has attacked the government over the revived TPP, claiming it would drive up drug prices ACTU president Ged Kearney says that the Trans Pacific Partnership, which is set …
Time for costly medicine monopolies to go from TPP trade talks
Time for costly medicine monopolies to go from TPP trade talks Belinda Townsend, Australian National University; Deborah Gleeson, La Trobe University; Hazel Moir, Australian National University; Joel Lexchin, University of …
New biologics course
Guild Learning and Development is partnering with AbbVie Pty Ltd in an online course titled “Understanding biologic medicines” AbbVie’s General Manager Kirsten O’Doherty says the course plays an important role …
Location rule certainty
Minister confirms a range of initiatives to boost pharmacy’s primary care role The Federal government is moving to give certainty to community pharmacy over location rules, Health Minister Greg Hunt …
Ageing population, air pollution to lift asthma meds uptake
The asthma medicines market is set to grow with incoming biologics and climbing disease rates, say market researchers The asthma therapeutics market in the Asia-Pacific region is expected to grow from …
Caution required for biosimilars
While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug …
Biosimilars: what’s in a name?
The way a biosimilar is named may affect whether a pharmacist is willing to substitute it for a brand name biologic, a new study has found. The study, published in …
Pfizer unveils last phase of Adelaide hub
Pfizer has unveiled the final phase of its $21 million investment which it says will establish Adelaide as a global manufacturing hub for a medicine commonly used to treat complications …